跳到正文
FDA 官方药品与生物制品信息·· 20 天前AI 评分31

FDA 撤回与过期指南清单更新:多份血液供者乙肝筛查指南于 2026-11-02 撤回

Withdrawn and Expired Guidances | Drugs

AI 导读

FDA 在撤回与过期指南清单中列出多份乙肝相关血液供者筛查指南,撤回日期均为 2026-11-02,涉及核酸 pooled/individual 样本检测、HBsAg 阳性供者复归及 Anti-HBc 检测等文件。清单同时收录肝损伤药代动力学指南(2026-09-01)及色谱方法验证审评指南(2024-11-25)等过期文件。

正文 · 原文

Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus10/01/201211/02/2026 Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection11/01/201111/02/2026 Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc)05/01/201011/02/2026 Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source Plasma and Source Leukocytes11/01/200711/02/2026 Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I)07/19/199611/02/2026 FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc)09/10/199111/02/2026 Recommendations for the Management of Donor and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg)12/02/198711/02/2026 Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling05/01/200309/01/2026 Reviewer Guidance, Validation of Chromatographic Methods11/01/199411/25/2024 ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin05/20/202107/28/2026 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product04/28/201503/09/2026 E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting09/12/200303/03/2026 Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets05/1/201303/03/2026 COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention05/17/202112/22/2023 Certification Process of Designated Medical Gases11/25/201512/18/2025 Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies12/20/201212/16/2025 Adverse Event Reporting to IRBs - Improving Human Subject Protection01/14/200912/16/2025 Cancer Drug and Biological Products - Clinical Data in Marketing Applications10/12/200109/17/2025 Oncologic Drug Advisory Committee Discussion on FDA Requirements for Approval of New Drugs for Treatment of Colon and Rectal Cancers04/19/198809/17/2025 FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer01/29/199109/17/2025 FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products12/01/199809/17/2025 Clinical Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry01/23/202011/05/2024 In Vitro Drug Interaction Studies — Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry01/23/202011/05/2024 Providing Submissions in Electronic Format—Summary Level Clinical Site Data for CDER's Inspection Planning12/19/20122/16/2018 CPG Sec. 440.100 Marketed New Drugs Without Approved NDAs and ANDAs09/21/201111/25/2020 Policy for Certain REMS Requirements During the COVID-19 Public Health Emergency Guidance for Industry and Health Care Professionals03/22/202011/07/2023 Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers05/17/202111/07/2023 Policy for the Temporary Use of Portable Cryogenic Containers Not in Compliance With 21 CFR 211.94(e)(1) For Oxygen and Nitrogen During the COVID-19 Public Health Emergency Guidance for Industry04/09/202011/07/2023 Marketed Unapproved Drugs -- Compliance Policy Guide04/09/202011/03/2023 Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics Guidance for Industry03/04/202006/02/2023 Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic*02/24/202205/11/2023 Development of Abbreviated New Drug Applications During the COVID-19 Pandemic--Questions and Answers04/21/202105/11/2023 Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency01/15/202105/11/2023 Review Timelines for Applicant Responses to Complete Response Letters When a Facility Assessment Is Needed During the COVID-19 Public Health Emergency Guidance for Industry12/21/202005/11/2023 Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency*09/10/202005/11/2023 Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing*06/19/202005/11/2023 Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency06/17/202005/11/2023 Effects of the COVID-19 Public Health Emergency on Formal Meetings and User Fee Applications--Questions and Answers05/27/202005/11/2023 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency04/06/202005/11/2023 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry04/20/202005/11/2023 Temporary Policy Regarding Non-Standard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency04/10/202005/11/2023 Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency04/22/202005/11/2023 Temporary Policy on Prescription Drug Marketing Act Requirements for Distribution of Drug Samples During the COVID-19 Public Health Emergency*06/08/202005/11/2023 Nonclinical Safety Evaluation of the Immunotoxic Potential of Drugs and Biologics Guidance for Industry03/04/202006/02/2023 Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic*02/24/202205/11/2023 Development of Abbreviated New Drug Applications During the COVID-19 Pandemic--Questions and Answers04/21/202105/11/2023 Protecting Participants in Bioequivalence Studies for Abbreviated New Drug Applications During the COVID-19 Public Health Emergency01/15/202105/11/2023 Review Timelines for Applicant Responses to Complete Response Letters When a Facility Assessment Is Needed During the COVID-19 Public Health Emergency Guidance for Industry12/21/202005/11/2023 Resuming Normal Drug and Biologics Manufacturing Operations During the COVID-19 Public Health Emergency*09/10/202005/11/2023 Good Manufacturing Practice Considerations for Responding to COVID-19 Infection in Employees in Drug and Biological Products Manufacturing*06/19/202005/11/2023 Statistical Considerations for Clinical Trials During the COVID-19 Public Health Emergency06/17/202005/11/2023 Effects of the COVID-19 Public Health Emergency on Formal Meetings and User Fee Applications--Questions and Answers05/27/202005/11/2023 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency04/06/202005/11/2023 Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry04/20/202005/11/2023 Temporary Policy Regarding Non-Standard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency04/10/202005/11/2023 Temporary Policy on Repackaging or Combining Propofol Drug Products During the COVID-19 Public Health Emergency04/22/202005/11/2023 Temporary Policy on Prescription Drug Marketing Act Requirements for Distribution of Drug Samples During the COVID-19 Public Health Emergency*06/08/2020  Classifying Significant Postmarketing drug safety issues3/01/20124/20/2020 Immunotoxicology Evaluation of Investigational New Drugs11/01/20022/19/2020 Diabetes Mellitus -- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes12/1/20083/9/2020 Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention3/1/20083/9/2020 Target Product Profile -- A Strategic Development Process Tool3/30/200712/13/2019 Qualification Process for Drug Development Tools1/6/201412/13/2019 Acceptance of Foreign Clinical Studies3/01/200112/06/2019 CPG Sec. 400.400 Conditions Under Which Homeopathic Drugs May be Marketed3/01/199510/24/2019 Analgesic Indications: Developing Drugs and Biological Products2/14/201408/23/2019 Guidelines for the Clinical Evaluation of Hypnotic Drugs9/01/199708/23/2019 Providing Regulatory Submissions in Electronic Format—Submission of Manufacturing Establishment Information12/29/201607/22/2019 Analgesic Indications: Developing Drug and Biological Products02/05/201406/20/2019 Establishing Pregnancy Exposure Registries08/01/200205/08/2019 In-Vivo Bioequivalence Studies Based on Population and Individual Bioequivalence Studies12/30/199706/10/1999 Attachment D – Application, Product, and Establishment Fees:  Common Issues and Their Resolution12/16/199411/08/2017 New Drug Evaluation Guidance Document: Refusal to File07/12/199305/19/2017 Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products; Availability02/26/199902/03/2000 Female Sexual Dysfunction: Clinical Development of Drug Products for Treatment05/16/200007/28/2010 Part 11, Electronic Records; Electronic Signatures, Electronic Copies of Electronic Records11/12/200202/04/2003 Guideline for the Clinical Evaluation of Analgesic Drugs12/01/199208/05/2003 Q1F: Stability Data Package for Registration Applications for Climactic Zones III and IV06/14/200211/21/2003 Clinical Evaluation of Antacid Drugs04/01/197807/20/2004 Clinical Evaluation of Antidiarrheal Drugs09/01/197707/20/2004 Clinical Evaluation of Gastric Secretory Depressant (GSD) Drugs09/01/197707/20/2004 Clinical Evaluation of Laxative Drugs04/01/197807/20/2004 Clinical Evaluation of Radiopharmaceutical Drugs10/01/198107/20/2004 FDA Requirements for Approval for Drugs to Treat Superficial Bladder Cancer06/01/198907/20/2004 Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing12/30/200304/01/2011 Preclinical Development of Antiviral Drugs11/01/199007/06/2005 Preclinical Development of Immunomodulatory Drugs for Treatment of HIV Infection and Associated Disorders09/04/199212/29/2005 Conjugated Estrogens, USP: LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence03/09/200008/12/2005 Organization of an Abbreviated New Drug Application03/02/199911/18/2005 BACPAC I: Intermediates in Drug Substance Synthesis; Bulk Actives Postapproval Changes:  Chemistry, Manufacturing, and Controls Information02/01/200106/01/2006 Drug Product: Chemistry, Manufacturing, and Controls Information01/01/200306/01/2006 Drug Substance: Chemistry, Manufacturing, and Controls Information01/01/200406/01/2006 Format and Content of the Chemistry, Manufacturing, and Controls Section of an Application02/01/198706/01/2006 Stability Testing of Drug Substances and Drug Products06/01/199806/01/2006 Submission of Chemistry, Manufacturing, and Controls Information for Synthetic Peptides11/01/199406/01/2006 Submitting Documentation for the Stability of Human Drugs and Biologics02/01/198706/01/2006 Providing Electronic Submissions in Electronic Format - ANDAs06/27/200209/29/2006 Providing Electronic Submissions in Electronic Format - NDAs01/28/199909/29/2006 Providing Regulatory Submissions in Electronic Format -- Annual Reports NDAs and ANDAs08/28/200309/29/2006 Q1F: Stability Data Package for Registration Applications for Climactic Zones III and IV07/01/200407/05/2006 Clinical Evaluation of Weight-Control Drugs09/01/199602/15/2007 Anti-Inflammatory and Anti-Rheumatic Drugs (Adults and Children)04/01/198805/29/2008 Labeling OTC Skin Protectant Drug Products06/04/200308/04/2008 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis02/11/200412/02/2009 Continuous Marketing Applications: Pilot 1 – Reviewable Units for Fast Track Products under PDUFA10/06/200304/09/2010 Continuous Marketing Applications: Pilot 2 – Scientific Feedback and Interactions during Development of Fast Track Products under PDUFA11/22/200404/09/2010 Continuous Marketing Applications: Pilot 2 – Scientific Feedback and Interactions during Development of Fast Track Products under PDUFA; Paperwork Reduction Act Burden Statement06/17/200304/09/2010 Clinical Evaluation of Lipid – Altering Agents08/14/199804/16/2010 Recommendations for Complying with the Pediatric Rule (21 CFR 314.55(a) and 601.27(a))12/04/200008/09/2010 Labeling Guidance for OTC Topical Drug Products for the Treatment of Vaginal Yeast Infections (Vulvovaginal Candidiasis)06/01/199810/17/2011 Consumer-Directed Broadcast Advertising of Restricted Devices01/26/200408/09/2010 Guideline on Validation of the Limulus Amebocyte Lysate Test12/01/198706/17/2011 Guideline for Validation of Amebocyte Lysate Test as an End-Product Endotoxin Test for Human and Animal Parenteral Drugs, Biological Products, and Medical Devices12/01/198707/08/2011 Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review09/01/200909/21/2011 Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling09/12/200602/21/2012 In Vivo Drug Metabolism/Drug Interaction Studies - Studn Design, Data Analysis and Recommendations for Dosing and Labeling11/24/199902/21/2012 Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies In Vitro04/07/199702/21/2012 Cholestyramine Powder In Vitro Bioequivalence01/15/199303/01/2012 Consumer-Directed Broadcast Advertising Questions and Answers08/09/199909/08/2012 Lupus Nephritis Caused By Systemic Lupus Erythematosus--Developing Medical Products for Treatment06/22/201006/27/2012 Manufacturing, Processing, or Holding Active Pharmaceutical Ingredients04/17/199808/07/2013 Powder Blends and Finished Dosage Units - Stratified In-Process Dosage Unit Sampling and Assessment11/07/200308/07/2013 Forms for Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution05/15/200108/07/2013 Disclosing Information Provided to Advisory Committees in Connection With Open Advisory Committee Meetings Related to the Testing or Approval of New Drugs and Convened by CDER, Beginning on January 1, 200012/22/199908/07/2013 Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products02/20/199708/07/2013 Empiric Therapy of Febrile Neutropenia; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Lyme Disease—Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Secondary Bacterial Infections of Acute Bronchitis—Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Streptococcal Pharyngitis and Tonsillitis; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Uncomplicated Urinary Tract Infections; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Uncomplicated Gonorrhea—Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Vulvovaginal Candidiasis; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Bacterial Vaginosis; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Acute Bacterial Meningitis; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Acute or Chronic Bacterial Prostatitis; Developing Antimicrobial Drugs for Treatment07/22/199808/07/2013 Developing Antimicrobial Drugs - General Considerations for Clinical Trials07/22/199808/07/2013 Catheter-Related Bloodstream Infections - Developing Antimicrobial Drugs For Treatment07/22/199808/07/2013 Labeling Over-the-Counter Human Drug Products; Updating Labeling in ANDA's02/22/200108/07/2013 Inhalation Drug Products Packaged in Semipermeable Container Closure Systems07/25/200208/07/2013 Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003-Questions and Answers
 11/19/200408/07/2013 Draft Guidance for Industry on Referencing Discontinued Labeling for Listed Drugs in Abbreviated New Drug Applications10/26/200008/07/2013 Submission of Patent Information for Certain Old Antibiotics12/03/200808/07/2013 Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug, and Cosmetic Act10/01/199908/07/2013 Labeling OTC Human Drug Products - Submitting Requests for Exemptions and Deferrals12/19/200010/28/2013 Enforcement Policy During Implementation of Section 503A of the Federal Food, Drug, and Cosmetic Act11/23/199809/22/2008 Providing Electronic Submissions in Electronic Format - ANDAs06/07/200206/11/2008 Providing Electronic Submissions in Electronic Format - NDAs01/28/199906/11/2008 Providing Regulatory Submissions in Electronic Format -- Annual Reports NDAs and ANDAs08/28/200306/11/2008 Phenytoin/Phenytoin Sodium Capsules, Tablets and Suspension In Vivo Bioequivalence and In Vitro Dissolution Testing12/01/200506/05/2014 Development of Parathyroid Hormone for the Prevention and Treatment of Osteoporosis06/14/200004/07/2015 Referencing Discontinued Labeling for Listed Drugs in Abbreviated New Drug Applications10/26/200004/07/2015 Accelerated Approval Products —Submission of Promotional Materials03/26/199905/06/2015 Providing Regulatory Submissions in Electronic Format - Prescription Drug Advertising and Promotional Labeling01/01/200105/06/2015 Comparability Protocols - Protein Drug Products and Biological Products - Chemistry, Manufacturing, and Controls Information 09/05/200305/06/2015 Notification to FDA of Issues that May Result in a Prescription Drug or Biological Product Shortage 02/21/201205/06/2015 Providing Regulatory Submissions in Electronic Format - General Considerations 10/01/200305/06/2015 Genotoxic and Carcinogenic Impurities in Drug Substances and Products: Recommended Approaches12/16/200805/28/2015 Using FDA-Approved Patient Labeling in Consumer-Directed Print Advertisements02/09/201508/06/2015 Malaria: Developing Drug and Nonvaccine Biological Products for Treatment and Prophylaxis06/07/200710/13/2015 Vaccinia Virus - Developing Drugs to Mitigate Complications from Smallpox Vaccination03/09/200403/05/2016 Exercise Induced Bronchospasms (EIB) Development of Drugs02/20/200205/10/2016 Classifying Resubmissions in Response to Action Letters05/14/199805/27/2016 Photosafety Testing05/07/200305/27/2016 Interim Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal, Food, Drug and Cosmetic Act12/04/201306/30/2016 Aerosol Steroid Products Safety Information in Prescription Drug Advertising and Promotional Labeling01/12/199810/21/2016 Assessment of Male-Mediated Developmental Risk for Pharmaceuticals06/12/201511/18/2016 Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions; Final03/18/200209/22/2017 Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions; Revision 101/27/200409/22/2017 M4: Granularity Annex: Final10/01/200510/04/2017 Drug Safety Information – FDA’s Communication to the Public -Draft03/08/201212/04/2017 Drug Safety Information – FDA’s Communication to the Public - Final03/02/200712/04/2017 Formal Meetings Between the FDA and Sponsors or Applicants - Final05/19/200912/27/2017 Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products- Draft03/10/201512/27/2017 Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices07/02/200912/13/2017 Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment (Revised Draft)05/19/201603/26/2018 Sinusitis: Designing Clinical Development Programs of Nonantimicrobial Drugs for Treatment11/01/200604/19/2018 Pediatric Oncology Studies In Response to a Written Request06/21/200004/30/2018 Formal Meetings Between the FDA and Biosimilar Biological Product Sponsors or Applicants11/17/201506/04/2018 Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommended Prescribing Information for Health Care Providers and Patient Labeling11/16/200506/07/2018 Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry09/21/201706/21/2018 Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis07/15/199908/22/2018 

来源:FDA 官方药品与生物制品信息 · fda.gov